Poseida Therapeutics, Inc. Operating Income
Poseida Therapeutics, Inc. reported Operating Income of $19.74 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2024-11-07
- Poseida Therapeutics, Inc. operating income (loss) for the quarter ending 2024-09-30 was $19.74M.
- Poseida Therapeutics, Inc. operating income (loss) for the quarter ending 2024-06-30 was -$31.76M.
- Poseida Therapeutics, Inc. operating income (loss) for the quarter ending 2024-03-31 was -$24.58M.
- Poseida Therapeutics, Inc. operating income (loss) for the quarter ending 2023-12-31 was -$25.91M.
- Poseida Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$129.50M.
- Poseida Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$59.95M.
- Poseida Therapeutics, Inc. operating income (loss) for fiscal 2021 was -$141.41M.
- Poseida Therapeutics, Inc. operating income (loss) for fiscal 2020 was -$126.55M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-09-30 | $19.74M 10-Q · filed 2024-11-07 | -$12.01M derived: sum of 2 quarters · filed 2024-11-07 | -$36.59M 10-Q · filed 2024-11-07 | -$62.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | -$31.76M 10-Q · filed 2024-08-05 | -$56.33M 10-Q · filed 2024-08-05 | -$82.24M derived: sum of 3 quarters · filed 2024-08-05 | -$118.46M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | -$24.58M 10-Q · filed 2024-05-14 | -$50.49M derived: sum of 2 quarters · filed 2024-05-14 | -$86.71M derived: sum of 3 quarters · filed 2024-11-07 | -$114.56M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | -$25.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$62.13M derived: sum of 2 quarters · filed 2024-11-07 | -$89.99M derived: sum of 3 quarters · filed 2024-11-07 | -$129.50M 10-K · filed 2024-03-07 |
| 2023-09-30 | -$36.22M 10-Q · filed 2024-11-07 | -$64.08M derived: sum of 2 quarters · filed 2024-11-07 | -$103.59M 10-Q · filed 2024-11-07 | -$136.81M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$27.86M 10-Q · filed 2024-08-05 | -$67.37M 10-Q · filed 2024-08-05 | -$100.59M derived: sum of 3 quarters · filed 2024-08-05 | -$28.81M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$39.52M 10-Q · filed 2024-05-14 | -$72.74M derived: sum of 2 quarters · filed 2024-05-14 | -$957.00K derived: sum of 3 quarters · filed 2024-05-14 | -$42.50M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$33.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $38.56M derived: sum of 2 quarters · filed 2024-03-07 | -$2.99M derived: sum of 3 quarters · filed 2024-03-07 | -$59.95M 10-K · filed 2024-03-07 |
| 2022-09-30 | $71.78M 10-Q · filed 2023-11-09 | $30.23M derived: sum of 2 quarters · filed 2023-11-09 | -$26.73M 10-Q · filed 2023-11-09 | -$44.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$41.55M 10-Q · filed 2023-08-08 | -$98.50M 10-Q · filed 2023-08-08 | -$115.98M derived: sum of 3 quarters · filed 2023-08-08 | -$157.57M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$56.96M 10-Q · filed 2023-05-09 | -$74.44M derived: sum of 2 quarters · filed 2023-05-09 | -$116.03M derived: sum of 3 quarters · filed 2023-05-09 | -$160.91M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$59.07M derived: sum of 2 quarters · filed 2023-03-09 | -$103.95M derived: sum of 3 quarters · filed 2023-03-09 | -$141.41M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$41.59M 10-Q · filed 2022-11-10 | -$86.47M derived: sum of 2 quarters · filed 2022-11-10 | -$123.93M 10-Q · filed 2022-11-10 | -$159.29M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$44.88M 10-Q · filed 2022-08-11 | -$82.34M 10-Q · filed 2022-08-11 | -$117.70M derived: sum of 3 quarters · filed 2022-08-11 | -$151.18M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$37.46M 10-Q · filed 2022-05-12 | -$72.82M derived: sum of 2 quarters · filed 2022-05-12 | -$106.30M derived: sum of 3 quarters · filed 2022-05-12 | -$135.74M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$35.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$68.83M derived: sum of 2 quarters · filed 2022-03-10 | -$98.28M derived: sum of 3 quarters · filed 2022-03-10 | -$126.55M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$33.47M 10-Q · filed 2021-11-09 | -$62.92M derived: sum of 2 quarters · filed 2021-11-09 | -$91.19M 10-Q · filed 2021-11-09 | -$114.40M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$29.45M 10-Q · filed 2021-08-12 | -$57.72M 10-Q · filed 2021-08-12 | -$80.93M derived: sum of 3 quarters · filed 2021-08-12 | -$101.69M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$28.27M 10-Q · filed 2021-05-11 | -$51.48M derived: sum of 2 quarters · filed 2021-05-11 | -$72.24M derived: sum of 3 quarters · filed 2021-05-11 | -$100.59M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$23.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$43.98M derived: sum of 2 quarters · filed 2021-03-11 | -$72.32M derived: sum of 3 quarters · filed 2021-03-11 | -$85.53M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$20.76M 10-Q · filed 2020-11-12 | -$49.11M derived: sum of 2 quarters · filed 2020-11-12 | -$62.32M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$28.34M 10-Q · filed 2020-08-20 | -$41.56M 10-Q · filed 2020-08-20 |